Egetis Therapeutics AB (publ) (P0F.SG)
Stuttgart · EUR · Healthcare · Biotechnology
€0.857 (+6.20%) as of
Key statistics
- Market cap
- 398.48M
- EPS (TTM)
- -0.0900
- Dividend yield
- 0.00%
- 52-week range
- 0.3770 – 0.8860
- Beta
- 0.78
- Profit margin
- 0.00%
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Stockholm, Sweden
- Employees
- 56
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.